Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Operating Expenses (2019 - 2025)

C4 Therapeutics' Operating Expenses history spans 7 years, with the latest figure at $34.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 20.34% year-over-year to $34.2 million; the TTM value through Dec 2025 reached $151.2 million, down 2.6%, while the annual FY2025 figure was $151.2 million, 2.6% down from the prior year.
  • Operating Expenses reached $34.2 million in Q4 2025 per CCCC's latest filing, down from $45.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $45.6 million in Q3 2025 to a low of $27.9 million in Q1 2021.
  • Average Operating Expenses over 5 years is $37.7 million, with a median of $39.0 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 55.38% in 2021, then fell 20.34% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $35.3 million in 2021, then grew by 16.45% to $41.1 million in 2022, then dropped by 1.12% to $40.7 million in 2023, then grew by 5.4% to $42.9 million in 2024, then fell by 20.34% to $34.2 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Operating Expenses are $34.2 million (Q4 2025), $45.6 million (Q3 2025), and $35.0 million (Q2 2025).